Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity

22 Jul 2022

Abstract excerpt

Oncogenic mutations in metabolic genes and associated oncometabolite accumulation support cancer progression but can also restrict cellular functions needed to cope with DNA damage. For example, gain-of-function mutations in isocitrate dehydrogenase (IDH) and the resulting accumulation of the oncometabolite D-2-hydroxyglutarate (D-2-HG) enhanced the sensitivity of cancer cells to inhibition of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Mitochondrial Function and Pathology
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35869047
DOI: 10.1038/s41419-022-05098-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivityPMID 35869047Read ↗

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivitySemantic proximity Read ↗

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting tumor mutation burdenSemantic proximity Read ↗

2-Hydroxyglutarate in Cancer Cells.Semantic proximity Read ↗

Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.Semantic proximity Read ↗

Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitorsSemantic proximity Read ↗

Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.Semantic proximity Read ↗

Metabolic Rewiring in the Face of Genomic Assault: Integrating DNA Damage Response and Cellular MetabolismSemantic proximity Read ↗

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.Semantic proximity Read ↗

SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors.Semantic proximity Read ↗

Glutamine Transporter SLC1A5 Regulates Ionizing Radiation‐Derived Oxidative Damage and FerroptosisSemantic proximity Read ↗

Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.Semantic proximity Read ↗

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.